Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California. Show more

Location: 3940 Trust Way, Hayward, CA, 94545, United States | Website: https://benitec.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

359.6M

52 Wk Range

$8.20 - $17.15

Previous Close

$13.70

Open

$13.90

Volume

4,653

Day Range

$13.88 - $14.00

Enterprise Value

257M

Cash

103.6M

Avg Qtr Burn

-4.667M

Insider Ownership

3.12%

Institutional Own.

90.69%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.